Brain Tumor: Keio University Cancer Vaccine

Brain Tumor: Keio University Cancer Vaccine

Brain Tumor: Keio University Cancer Vaccine

• August 21, 2020
• Reading time: 2 minutes

Due to the global impact of the COVID-19 pandemic, vaccine development and antiviral drug production have become key focuses worldwide, with countries dedicating substantial resources to pandemic response. Simultaneously, Japan is conducting research on cancer vaccines. This article presents clinical trials being conducted at the Department of Neurosurgery at Keio University School of Medicine. The distinctive feature involves developing a peptide-based cancer vaccine targeting VEGFR1&2, which is administered via injection into the axilla or groin. The trial recruits patients with: ① Initial/advanced/recurrent malignant glioma ② Neurofibromatosis ③ Advanced/recurrent treatment-resistant brain tumors, each receiving different peptide-based cancer vaccines. Notably for ③, patients must have no other effective treatment options available.

To develop the cancer vaccine, HLA (Human Leukocyte Antigen) typing information is required. Some patients have inquired whether self-tested HLA reports can be submitted. While self-reported results may serve as reference, official HLA testing from an HLA research institute is required. Testing from other institutions is not accepted by the hospital.

If approved, depending on tumor type and treatment approach, clinical trial participation lasts approximately 8-12 months, with costs ranging from approximately ¥250,000-500,000. Uninsured foreign patients may incur additional medical expenses. This article is provided for reference only; accurate information should be obtained from the hospital's official website and clinical trial registration data.

Clinical trial information can be found at:

https://jrct.niph.go.jp/latest-detail/jRCTs031180148

https://jrct.niph.go.jp/latest-detail/jRCTs031180170

【Note】The clinical trial data and pharmaceutical information from overseas trials translated by "Medical Supporter" do not constitute an endorsement of participation in clinical trials or the use of new drugs. Additionally, the translated materials are for reference only and should not be considered as treatment guidelines. Please discuss with healthcare professionals, and refer to the original text at the bottom of the article for accurate information.

Data Source: http://www.neurosurgery.med.keio.ac.jp/clinical/index.html

① Hexapeptide Cocktail Vaccine Against Advanced/Recurrent Malignant Glioma

② VEGFR1/2 Peptide Vaccine Therapy for Initial Malignant Glioma

③ VEGFR1/2 Peptide Vaccine Against Type 2 Advanced Neurofibromatosis

④ VEGFR1/2 Peptide Vaccine for Advanced/Recurrent Treatment-Resistant Brain Tumors

※ ④ Target Diseases

Chordoma, Meningioma, Hemangiopericytoma, Hemangioblastoma, Ependymoma

→ Applicable when effective treatments such as surgery or radiation therapy are unavailable for the above brain tumors

• Immunotherapy

• Clinical Trial Drug

  (Lung Cancer) Topotecan and Topotecan + Berzosertib Show Promising Results in Phase II Trial. (Lung Cancer) HER2 Gene Mutation Non-Small Cell Lung Cancer: Is Enhertu Effective? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4